Pfizer Inc. has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK's trametinib (GSK1120212) combined with Pfizer's palbociclib (PD-0332991) in a Phase I/II study (Study 200344) in patients with advanced/metastatic melanoma.

Advances in cancer therapy are expected in the next years thanks in particular to treatment using antibody-drug conjugates and multi-kinase inhibitors. This is the finding from a TNS Emnid survey of medical experts at the "Science For A Better Life" symposium organized by Bayer. This event saw 380 scientists from 14 countries come together at the Bayer Kasino in Leverkusen in November.

A simple low-cost device that helps newborn babies to breathe and has the potential to transform the life chances for thousands of African babies has been awarded the highest fund in the first GSK and Save the Children $1 million Healthcare Innovation Award.

The Bristol-Myers Squibb Foundation has marked World Diabetes Day and the third anniversary of its Together on Diabetes initiative by announcing four new grants focusing on the important link between type 2 diabetes, depression and distress. Together on Diabetes also issued its third annual report.

In honor of World Diabetes Day, Abbott has created an interactive infographic to help raise awareness about what life can be like for an insulin-using patient who has diabetes. Approximately 26 percent of the 18.8 million Americans diagnosed with diabetes follow an insulin regimen recommended by their healthcare provider in order to manage their condition.

Novartis announced today interim results from a Phase 1 clinical trial with its proprietary cell culture vaccine for the H7N9 avian influenza virus involving 400 healthy volunteers (18-64 years of age). The data shows 85% of subjects achieved a protective immune response after two doses of the 15 ug MF59 adjuvanted vaccine.

Bristol-Myers Squibb Company (NYSE:BMY) has announced a series of related changes within its Senior Management Team. To support its ongoing success as a BioPharma leader, the company is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization.